Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer

48:15
 
Share
 

Manage episode 409274058 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:

  • Rationale for targeting PARP in prostate cancer with ARI combinations
  • Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
  • FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
  • Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
  • Tips for optimal coordination between pathology and medical oncology

Presenters:

Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington

Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.

Link to full program:
https://bit.ly/3PFagxb

  continue reading

179 episodes

Artwork
iconShare
 
Manage episode 409274058 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:

  • Rationale for targeting PARP in prostate cancer with ARI combinations
  • Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
  • FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
  • Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
  • Tips for optimal coordination between pathology and medical oncology

Presenters:

Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington

Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.

Link to full program:
https://bit.ly/3PFagxb

  continue reading

179 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide